Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, pharmacokinetics, and efficacy of 100, 150, and 200 mg risedronate in postmenopausal women with low bone mineral density has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Actonel (risedronate)
• risedronate (risedronate)

Snippet

Sponsor: Warner Chilcott | Conditions: Postmenopausal | Phase 2 | Status: COMPLETED